The term “oligometastatic prostate cancer” refers to a heterogeneous group of disease states
currently defined solely on the basis of clinical features. Oligorecurrent disease, de novo …

Background Recognizing the rapidly increasing interest and evidence in using metastasis-
directed radiotherapy (MDRT) for oligometastatic disease (OMD), ESTRO and ASTRO …

Background Due to improved imaging sensitivity, the term “oligometastatic” prostate cancer
disease is diagnosed more often, leading to an increasing interest in metastasis-directed …

Target volume delineations for prostate cancer (PCa) salvage radiotherapy (SRT) after
radical prostatectomy are usually drawn in the absence of visibly recurrent disease. 68Ga …

Background: The aim of the present study is to evaluate the impact of metastases-directed
stereotactic body radiotherapy in two groups of oligometastatic prostate cancer (PC) …

Background The management of oligometastatic prostate cancer (PCa) remains
controversial, especially following the introduction of prostate-specific membrane antigen …

Purpose: Outcomes for resistant metastatic castration-resistant prostate cancer (CRPC) are
poor. Stereotactic ablative radiotherapy (SABR) induces antitumor immunity in clinical and …

Objective To investigate the peri‐operative and oncological outcomes of robot‐assisted
radical prostatectomy (RARP) in patients with oligometastatic prostate cancer (PC a) …

Background Oligometastatic disease in prostate cancer (PCa) is a challenging clinical
scenario encountered more frequently with the widespread adoption of PSMA-PET. SBRT …

Purpose The aim of this study was to evaluate the outcomes of 68 Ga prostate-specific
membrane antigen (68 Ga-PSMA) positron-emission tomography (PET)/CT-based …